Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Cortes, J. E.; Tallman, M. S.; Schiller, G.; Trone, D.; Gammon, G.; Goldberg, S.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Levis, M. |
| Abstract Title: | Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) |
| Meeting Title: | 55th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 122 |
| Issue: | 21 |
| Meeting Dates: | 2013 Dec 7-10 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2013-11-15 |
| Language: | English |
| ACCESSION: | WOS:000331385001094 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V122.21.494.494 |
| Notes: | Meeting Abstract: 494 -- Source: Wos |
